688321 微芯生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.3433.178-6.9635.5091.192
总资产报酬率 ROA (%)0.6871.477-3.5502.9130.730
投入资产回报率 ROIC (%)0.7661.652-3.9093.3360.856

边际利润分析
销售毛利率 (%)85.79887.11886.70689.12294.341
营业利润率 (%)11.2425.506-27.13018.5353.014
息税前利润/营业总收入 (%)13.9797.863-12.52721.5883.418
净利润/营业总收入 (%)10.9995.600-17.4139.3922.418

收益指标分析
经营活动净收益/利润总额(%)113.380127.94280.209-201.58222.558
价值变动净收益/利润总额(%)-17.242-49.62322.335290.69515.832
营业外收支净额/利润总额(%)-0.852-0.119-84.572-0.055-5.388

偿债能力分析
流动比率 (X)2.5641.3992.4012.8922.191
速动比率 (X)2.4921.3302.3102.7712.138
资产负债率 (%)43.59255.46351.36446.62045.587
带息债务/全部投入资本 (%)34.55144.87242.10134.16729.849
股东权益/带息债务 (%)179.447112.777127.070172.198209.878
股东权益/负债合计 (%)129.40180.30194.688114.500114.800
利息保障倍数 (X)4.9363.327-5.7697.0496.129

营运能力分析
应收账款周转天数 (天)101.87288.40997.360120.07389.983
存货周转天数 (天)143.138151.278181.037238.879263.140